Clinical trials: Urinary
Overactive Bladder, Overactive Bladder Syndrome
Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection
The goal of this clinical trial is to evaluate the outcomes of differing durations of antibiotic prophylaxis with bladder onabotulinumtoxinA injection in patients with refractory overactive bladder.
- Conditions
- Overactive Bladder, Overactive Bladder Syndrome, Urge Incontinence, Urinary Incontinence, Urge
- Trial name
- NCT05719285
- Testing
- Single-Dose Antibiotic, Multi-Dose Antibiotic
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Transitional Cell Carcinoma
Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas
RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. Biological therapies, such as Bacille Calmette Guerin (BCG) and sargramostim (GM-CSF), use different ways to stimulate the…
- Trial name
- NCT00070070
- Testing
- TICE®-strain BCG, NY-ESO-1 protein, sargramostim
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Ludwig Institute for Cancer Research
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth and by blocking blood flow to the tumor.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00397488
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neurogenic Detrusor Overactivity
A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity
This study will evaluate the pharmacodynamics and pharmacokinetics of darifenacin liquid oral suspension in children, ages 2-15 years, with neurogenic detrusor overactivity.
- Trial name
- NCT00712322
- Testing
- Darifenacin
- Where
- 12 sites in United States, Colombia
- Volunteers
- 35 people
- Sponsor
- Warner Chilcott
Chronic Interstitial Cystitis
A Safety, Tolerability and Preliminary Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis (IC) and Hunner's Lesions
The purpose of the study is to evaluate if LiRIS 400 mg is safe and tolerable when administered to women with Interstitial Cystitis with Hunner's lesions, and to evaluate any change in the bladder or in IC symptoms, following…
- Trial name
- NCT01879683
- Testing
- LiRIS® 400 mg
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Allergan
Bladder Cancer
S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer
The primary focus of this study is to see if looking at tumor biomarkers using a program called coexpression extrapolation or "COXEN" may predict a patient's response to chemotherapy before surgery.
- Trial name
- COXEN (NCT02177695)
- Testing
- Gemcitabine, Cisplatin, Methotrexate
- Where
- 566 sites in United States
- Volunteers
- 237 people
- Sponsor
- SWOG Cancer Research Network
Non-Transitional Cell Carcinoma of the Urothelial Tract, Small Cell of the Bladder
Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract
This study is being done test to test the safety and effectiveness of durvalumab combined with tremelimumab in patients who have a rare form of cancer of the urinary tract.
- Conditions
- Non-Transitional Cell Carcinoma of the Urothelial Tract, Small Cell of the Bladder, Adenocarcinoma of the Bladder, Squamous Cell Carcinoma of the Bladder
- Trial name
- NCT03430895
- Testing
- durvalumab and tremelimumab
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Urinary Retention, Lower Urinary Tract Symptoms
Tamsulosin vs Placebo to Prevent Postoperative Urinary Retention in Female Pelvic Reconstructive Surgery
This is a placebo controlled randomized controlled trial of perioperative use of tamsulosin to prevent postoperative urinary retention in female pelvic reconstructive surgery.
- Conditions
- Urinary Retention, Lower Urinary Tract Symptoms, Stress Urinary Incontinence, Pelvic Organ Prolapse
- Trial name
- NCT03524339
- Testing
- Tamsulosin
- Where
- 2 sites in United States
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Pain, Neuropathic, Epilepsy
Cancer in Patients With Gabapentin (GPRD)
High doses of gabapentin are associated with pancreatic acinar cell tumors in rats, but there has been no post marketing pancreatic carcinogenicity signal with gabapentin as reported by spontaneous reports in AERS or in the…
- Conditions
- Pain, Neuropathic, Epilepsy, Renal Pelvis Cancer, Pancreatic Cancer
- Trial name
- NCT01236053
- Testing
- Gabapentin prescriptions
- Volunteers
- 2,323,608 people
- Sponsor
- GlaxoSmithKline
Ovary Cancer, Cervix Cancer
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
The purpose of the trial is to establish the tolerability of HuMax-TF-ADC in a mixed population of patients with specified solid tumors.
- Conditions
- Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer
- Trial name
- NCT02001623
- Testing
- Tisotumab Vedotin (HuMax-TF-ADC)
- Where
- 29 sites in United States, Belgium and 3 more
- Volunteers
- 195 people
- Sponsor
- Seagen Inc.
Overactive Bladder (OAB)
Drug Use Investigation for Toviaz
The purpose of this study is to collect effectiveness and safety information of fesoterodine related to their appropriate use in daily practice.
- Trial name
- NCT01936870
- Testing
- Fesoterodine (Toviaz)
- Volunteers
- 2,521 people
- Sponsor
- Pfizer
Lower Urinary Tract Symptoms
Pilot Trial Of Urinary Nerve Growth Factor (NGF) As Biomarker for Male Lower Urinary Tract Symptoms
A single center, pilot trial using tamsulosin and solifenacin in 10 men with symptomatic lower urinary tract symptoms (LUTS). Subjects will be evaluated at baseline, 1, 2, and 3 months for urinary NGF, urine creatinine, NGF/CR…
- Trial name
- LUTS (NCT01457573)
- Testing
- Tamsulosin, Solifenacin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Timothy Boone, MD, PhD
Low Anterior Resection Syndrome, Malignant Anal Neoplasm
Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study
This phase II trial studies how well sacral nerve stimulation works in treating low anterior resection syndrome or fecal incontinence (the body's passage of stool without control) in patients with rectal cancer that has spread to…
- Conditions
- Low Anterior Resection Syndrome, Malignant Anal Neoplasm, Malignant Bladder Neoplasm, Malignant Cervical Neoplasm
- Trial name
- NCT04066894
- Testing
- Explantation, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Urinary Tract Infections
Safety, Tolerability and Pharmacokinetic Investigation of GSK3882347 in Healthy Participants.
This is a phase 1, 2-part, double-blind (sponsor-unblinded), randomized, placebo-controlled, first time in human (FTIH) study, that includes both single-ascending and multiple-ascending dose phase to assess the safety…
- Trial name
- NCT04488770
- Testing
- GSK3882347
- Where
- United Kingdom
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Overactive Bladder
A Single Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Participants With Renal Insufficiency (MK-4618-014)
This study will investigate the impact of impaired renal function on the plasma pharmacokinetics of vibegron (MK-4618) to guide use of vibegron in clinical trials in participants with overactive bladder and to guide…
- Trial name
- NCT01628042
- Testing
- Vibegron 100 mg
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Urinary Incontinence
Acupuncture for Urinary Incontinence
This research study will evaluate the effectiveness of acupuncture in decreasing urinary incontinence (involuntary urine loss) in women. The study will involve 12 acupuncture sessions over 6 weeks.
- Trial name
- NCT00297427
- Testing
- Acupuncture
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- University of Pittsburgh
Stress Urinary Incontinence
Disposable Stress Urinary Incontinence Pessary Device Study
This study is an interventional, single arm, multi-center study. It will be conducted at sites in the northeastern United States. The protocol will be approved by Chesapeake IRB or applicable local IRBs.
- Trial name
- NCT03323723
- Testing
- SUI Device
- Where
- 3 sites in United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Rinovum Women's Health, Inc.
Postoperative Urinary Tract Infection, Laparoscopic Hysterectomy
Effect of Vulvar Re-Antisepsis Before CO₂ Cystoscopy Performed After Laparoscopic Hysterectomy on Postoperative Urinary Infections
This prospective observational study aims to evaluate whether additional vulvar re-antisepsis before intraoperative cystoscopy reduces the incidence of postoperative urinary tract infections (UTIs) in patients undergoing total…
- Conditions
- Postoperative Urinary Tract Infection, Laparoscopic Hysterectomy, Cystoscopy, Antisepsis
- Trial name
- NCT07232446
- Testing
- Additional Vulvar Re-Antisepsis Before Cystoscopy
- Where
- Turkey (Türkiye)
- Volunteers
- 98 people
- Sponsor
- Alaattin Karabulut
Kidney Stones
Trial of Randomized Antibiotic Administration in Percutaneous Nephrolithotomy
The Investigators objective is to compare the clinical efficacy of a single-day protocol with a short-course protocol for PCNL. The investigator hope is to reduce the use of possibly unnecessary prolonged antibiotic use, reduce…
- Trial name
- NCT02579161
- Testing
- cephalosporins, Fluoroquinolones, Clindamycin
- Where
- 2 sites in United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Bladder Cancer, Melanoma
Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
The purpose of this study is to investigate the characteristics of tumors in patients treated with nivolumab and to identify features that help to predict a good or bad response to this drug.
- Trial name
- NCT02553642
- Testing
- Nivolumab, Nivolumab plus Ipilimumab
- Where
- 5 sites in United States
- Volunteers
- 81 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.